Evidence map›Paper›PMID 38444268›Full record

ArticleAmerican journal of hematology2024

Results of a phase I trial with Haploidentical mbIL-21 ex vivo expanded NK cells for patients with multiply relapsed and refractory AML.

Stefan O Ciurea, Piyanuch Kongtim, Samer Srour, Julianne Chen, Doris Soebbing, Elizabeth Shpall, Katayoun Rezvani, Robin Nakkula, Aarohi Thakkar, Ella C Troy and 6 more

Open access · bronzeAbstract readClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of hematology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 3 pooled it
6.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 3 syntheses or guidelines pooled it, 25 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. CXCL10-induced chemotaxis ofMolecular therapy. Oncology · 2025
    Article
  12. Review
  13. Review
  14. Review
  15. Strategic innovations: Tackling challenges of immunotherapy in acute myeloid leukemia.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2025
    Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Feeder-cell-free system forFrontiers in immunology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 5 institutions in 2 countries.

Stefan O CiureaHematopoietic Stem Cell Transplant and Cellular Therapy Program, Division of Hematology/Oncology, The University of California, Orange, California, USA.ORCID 0000-0001-8597-3271
Piyanuch KongtimHematopoietic Stem Cell Transplant and Cellular Therapy Program, Division of Hematology/Oncology, The University of California, Orange, California, USA.
Samer SrourDepartment of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID 0000-0002-6693-2025
Julianne ChenDepartment of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Doris SoebbingDepartment of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Elizabeth ShpallDepartment of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Katayoun RezvaniDepartment of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Robin NakkulaThe Abigail Wexner Research Institute, Columbus, Ohio, USA.
Aarohi ThakkarThe Abigail Wexner Research Institute, Columbus, Ohio, USA.
Ella C TroyThe Abigail Wexner Research Institute, Columbus, Ohio, USA.
Alex A CashThe Abigail Wexner Research Institute, Columbus, Ohio, USA.
Gregory BehbehaniThe Abigail Wexner Research Institute, Columbus, Ohio, USA.
Kai CaoDepartment of Laboratory Medicine, Division of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Jolie SchaferSanofi S.A., Bridgewater, New Jersey, USA.
Richard E ChamplinDepartment of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Dean A LeeThe Abigail Wexner Research Institute, Columbus, Ohio, USA.
The University of Texas MD Anderson Cancer Center · USThe Ohio State University Wexner Medical Center · USThe Japanese Data Center for Hematopoietic Cell Transplantation · JPNationwide Children's Hospital · USSanofi (United States) · US

Funding

Univ.of Calif., Irvine Cancer Center Support GrantP30CA062203 · NCI · UNIVERSITY OF CALIFORNIA-IRVINE · PI Melanie Funes · 1994 to 2026
$57.9M
NCI NIH HHS P30 CA062203The Leukemia and Lymphoma Society 6149-14The Taylor Trudeau Cycle for Life Charitable FoundationThe University of Texas MD Anderson Cancer Center High Impact Clinical Research Support Program and Moonshot Initiative
6 · The paper itself

Abstract

Natural killer (NK)-cells have potent anti-tumor effects, yet it remains unclear if they are effective for patients with relapsed acute myeloid leukemia (AML). In a phase I clinical trial, we treated 12 patients (median age 60 years) with refractory AML (median 5 lines of prior therapy, median bone marrow blast count of 47%) with fludarabine/cytarabine followed by 6 infusions of NK-cells expanded from haploidentical donors using K562 feeder cells expressing membrane-bound IL21 and 4-1BBL. Patients received 10

Indexed as

Graft vs Host DiseaseLeukemia, Myeloid, AcuteCytarabineHaplotypesHumansKiller Cells, NaturalMiddle AgedCytarabine

Identifiers

PMID38444268
PMCPMC12577216
OpenAlexW4392516736

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.